Superior Court Upholds $70M Risperdal Verdict
A Pennsylvania Superior Court has rejected Johnson & Johnson’s appeal of a 2016 $70 million verdict awarded to a 20 year-old Tennessee man, Andrew Yount (A.Y.) who developed gynecomastia after taking the antipsychotic drug Risperdal since he was 4-1/2 years old. Gynecomastia is an irreversible condition caused by an increase in the hormone prolactin and […]
J&J CEO May Testify in Risperdal Trial
Updated January 30, 2019 The eighth Risperdal case is set to go to trial, this time the stakes are even higher for both sides as the jury may award punitive damages to the plaintiff if wrongful conduct by Johnson & Johnson is proven. “We’re excited about the availability of punitive damages. All along, we thought […]
Superior Court Allows Punitive Damages in Risperdal Mass Torts
In a significant ruling by the Pennsylvania Superior Court, Janssen, a subsidiary of Johnson & Johnson (J&J), will now face punitive damages in Risperdal mass tort suits. A previous Philadelphia trial court ruling prohibited punitive damages. Boys and young men who developed gynecomastia, female-like breasts, from taking the antipsychotic drug and whose cases had already […]
High Court Won’t Hear Sheller Dispute with FDA over Risperdal
High Court Won’t Hear Dispute Challenging FDA Over J&J Drug Supreme Court won’t weigh in on whether law firm can sue FDA over drug labeling Circumstances in which third parties can sue over government actions remain unclear By Dana A. Elfin A Philadelphia-based law firm has hit the end of the road in its bid […]
Researchers Concerned About Over-Prescription of Risperdal
The most recent study published on the use of antipsychotics, such as Risperdal, Zyprexa and Seroquel, in children with ADHD has researchers concerned that there may be an over-prescription problem. The study published January 19, 2017 in The Canadian Journal of Psychiatry shows the same dramatic increase in use of antipsychotics prescribed off-label in children with ADHD, ages 1 […]
$2.2B Settlement “Leads the Pack”
The $2.2 Billion Settlement with Johnson & Johnson Leads the Pack by Lizzy McLellan, The Legal Intelligencer The Legal Intelligencer reported that the largest verdict and settlement award in Pennsylvania between August 2013 and August 2014 was handled by Sheller, P.C. with a $2.2 billion settlement over healthcare giant Johnson & Johnson and its subsidiary, […]
Sheller on Lawyer Spars With FDA Over J&J Risperdal Court Documents
Pharmalot.com, Pharmaceutical Industry News 2013-07-11 In an unusual tactic, an attorney is prodding the FDA to seek documents that purportedly detail side effects caused by the Risperdal antipsychotic, but cannot be released publicly due to a court order. The documents were sealed by a Philadelphia judge as part of ongoing litigation over claims the Johnson […]
In The New York Times: “Side Effects May Include Lawsuits”
One of the most-read articles in The New York Times regarding pharmaceutical drug product liability and whistleblower lawsuits quotes Stephen Sheller. Side Effects May Include Lawsuits BY DUFF WILSON NEW YORK – FOR decades, antipsychotic drugs were a niche product. Today, they’re the top-selling class of pharmaceuticals in America, generating annual revenue of about $14.6 billion […]
